Biological aging markers did not explain cognition or depression in this HIV cohort
In a cohort of 238 women, biological aging measures failed to map cleanly onto neurocognitive performance or depressive symptoms, even though prior work in the same population had already shown evidence of accelerated aging in women living with HIV. The study looked at multiple layers of aging biology at once: absolute telomere length, mitochondrial DNA copy number, MRI-based brain-predicted age difference, and a panel of DNA methylation age acceleration metrics including Horvath, Hannum, PhenoAge, Horvath intrinsic epigenetic age acceleration, Hannum intrinsic epigenetic age acceleration, and extrinsic epigenetic age acceleration. The analytic design was built to answer a clinically important question: do these biomarkers help explain why cognitive impairment and depression remain common in people with HIV, or are they biologically interesting but clinically detached from daily symptoms?
The answer, at least in this dataset, leaned toward detachment. Biological aging markers were not associated with either global cognitive deficit scores or depressive symptom burden after regression modeling. The absence of a consistent signal across telomeres, mitochondrial copy number, MRI-derived brain aging, and epigenetic clocks suggests that the cognitive and psychiatric burden in this group cannot be reduced to a single aging pathway. In practical terms, that means the bedside explanation for memory, attention, or mood complaints in women with HIV is unlikely to be captured by one laboratory measure, no matter how sophisticated that measure may be.
HIV status modified a few nominal signals, but none held after correction
A narrower pattern emerged when HIV status entered the models. HIV infection combined with higher mitochondrial DNA copy number and higher extrinsic epigenetic age acceleration was nominally associated with worse global deficit scores, with p values of 0.012 and 0.047, respectively. Those associations did not survive correction for multiple testing, which sharply reduces the likelihood that they represent durable findings rather than statistical noise in a multi-marker analysis. The result leaves open a familiar problem in aging biomarker research: once several overlapping indices are tested in parallel, isolated positive findings can appear persuasive before the full error structure is accounted for.
One sentence captures the core result: no biomarker consistently predicted cognition after statistical correction.
Biologically, the partial signal around mitochondrial DNA copy number is plausible but not definitive. Mitochondria sit at the center of cellular energy handling, oxidative stress, and inflammatory signaling, all of which could influence neuronal resilience and cognitive efficiency in chronic HIV infection. Yet plausibility is not proof. The data here do not show that mitochondrial dysregulation is driving neurocognitive decline; they only suggest that this pathway may deserve attention in larger cohorts where effect estimates can be stabilized and false-positive findings are less likely to dominate interpretation.
Childhood maltreatment did not reshape the biomarker-symptom relationship
The same logic held for childhood maltreatment. Severe early-life adversity is a strong risk factor for later psychiatric symptoms and has been linked to enduring stress-system dysregulation, inflammatory activation, and altered aging biology. Even so, interaction models found no evidence that HIV status or childhood maltreatment moderated the association between biological aging markers and depressive symptoms. The absence of moderation matters because it argues against a simple vulnerability model in which early trauma or HIV infection amplifies the clinical impact of aging biomarkers in a predictable way.
The study therefore separates two ideas that are often conflated in clinical conversation. One is that women with HIV may show accelerated biological aging. The other is that these aging signatures automatically explain why some patients develop depression or cognitive impairment while others do not. The first idea is supported by the group’s prior work. The second is not supported here. That gap points toward a more complex model in which mood and cognition are shaped by psychiatric history, social stress, vascular risk, medication exposure, sleep, substance use, and immune factors in addition to any measurable aging signal.
Why the negative finding still matters for clinical interpretation
Negative biomarker studies can be easy to dismiss, but this one has a clear clinical message: accelerated biological aging does not necessarily translate into measurable neuropsychiatric dysfunction at a single time point. For clinicians following women with HIV, the finding argues against using aging biomarkers as stand-alone proxies for cognitive screening or depression risk stratification. A patient can have evidence of biologic aging without manifesting worse global deficit scores or higher depressive symptom scores on the measures used here.
The study also reinforces the limits of cross-sectional inference. If aging markers do influence cognition or mood, the effect may be delayed, nonlinear, threshold-based, or restricted to particular subgroups not resolved in the present cohort. A single snapshot cannot capture the tempo of change. Longitudinal follow-up will be needed to determine whether these biomarkers forecast later decline, whether they track worsening symptoms over time, or whether their main utility lies elsewhere, such as in characterizing cumulative physiologic stress rather than predicting psychiatric outcomes.
The cohort itself was specific: 238 women, including 122 women with HIV. That focus improves internal coherence but narrows generalizability, especially to men, older adults, and populations with different comorbidity patterns or treatment exposures. The study also relied on a preprint that has not yet undergone peer review, so the analysis should be read as an early contribution rather than settled evidence. Still, the message is clinically useful because it prevents overinterpretation of biologic aging assays in neuroHIV care. Aging biology may be real, and meaningful, without being the immediate explanation for cognitive or depressive symptoms.
What larger longitudinal studies will need to answer
Future work will need to establish whether any of these biomarkers predict change rather than status, and whether their behavior differs by ART exposure, duration of infection, vascular comorbidity, or repeated trauma. It will also be important to test whether more refined neuropsychological endpoints reveal domain-specific effects that global deficit scores obscure. Inflammation, endocrine function, sleep quality, and social adversity may prove more informative than aging markers alone when the outcome is depression or cognition in women living with HIV.
For now, the study leaves a restrained but important conclusion: accelerated biological aging was evident in this population, yet the link to cognitive impairment and depressive symptoms remained weak, inconsistent, and statistically unconvincing after correction. That pattern argues for broader mechanistic models, not simpler biomarker substitution, when evaluating neuropsychiatric health in HIV.